Screening Genetic Alterations of Biomarkers BRAF, ROS-1, and HER2 by Immunohistochemistry in Ovarian Carcinomas for Targeted Therapy

Xiaobing Deng, PhD, Jian-Jun Wei, MD, Shengle Zhang, MD


Ovarian neoplasms are group of aggressive and lethal diseases.  Surgical and radiochemical therapies on ovarian neoplasm are conventional approaches but with limited progress in years.  Targeted therapy with drugs targeting specific genetic alterations and/or protein molecules have brought new hope fighting against ovarian neoplasms.  Targeted therapy on genetic alterations of BRAF, ROS-1 and HER2 have been carried out in melanoma, lung cancer and breast cancer with promising results.  However, knowledge of these genetic alterations in ovarian neoplasms is limited and deserves further exploration.  In this study, we screened genetic alterations of BRAF, ROS-1 and HER2 by immunohistochemistry (IHC) on a variety of ovarian neoplasm, including 13 mucinous carcinomas, 12 clear cell carcinomas, 9 endometrioid carcinomas, 9 serous borderline tumors and 10 high grade serous tumor of fallopian tube.  Although ROS-1 and HER2 abnormalities were not identified, BRAF V600E mutations were identified in 2 of 9 (22%) in borderline serous tumors.  This finding has provided a knowledge base to further study the possibility of targeted therapy using BRAF inhibitor, such as vemurafeni, on borderline serous tumor of the ovary.       

[N A J Med Sci. 2017;10(2):53-55.   DOI:  10.7156/najms.2017.1002053]


ovarian cancer, targeted therapy, BRAF, ROS-1, HER2

Full Text:



Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.

Banerjeer S and Kaye SB. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin Cancer Res. 2013;19:961-968.

Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29:3366-3373.

Davies KD, Le AT, Theodoro MF, et al. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res. 2012;18:4570-4579.

Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurfenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2516.

Bookman MA, Darcy KM, Clarke-Pearson D, et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol. 2003;21(2):283-290.

Ray-Coquard I, Guastalla JP, Allouache D, et al. HER2 overexpression/ amplification and trastuzumab treatment in advanced ovarian cancer: a GINECO phase II study. Clin Ovarian Cancer. 2008;1:54-59.

Grisham RN, Iyer G, Garg K, et al. BRAF Mutation is associated with early stage disease and improved outcome in patents with low-grade serous ovarian cancer. Cancer. 2013;119:548-554.

Bösmüller H, Fischer A, Phamb DL, et al. Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR. Human Pathol. 2013;44:329-335.

Hayashi Y, Sasaki H, Takeshita S, et al. Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in ovarian serous borderline tumors. Oncol Rep. 2014;32:1815-1819.

Bledsoe JR, Kamionek M, Mino-Kenudson M. BRAF V600E Immunohistochemistry is reliable in primary and metastatic colorectal carcinoma regardless of treatment status and shows high intratumoral homogeneity Am J Surg Pathol. 2014;38:1418-1428.


  • There are currently no refbacks.